

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **INSIDE INFORMATION**

### **UPDATE ON GLOBAL REGISTRATIONAL STRATEGY FOR IMM2510 FOR NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**,” together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated August 1, 2024, in relation to the license and collaboration agreement, dated August 1, 2024, by and between the Company and SynBioTx Inc., a wholly-owned subsidiary of Instil Bio, Inc. (NASDAQ: TIL, “**Instil**”).

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce a global registrational strategy in collaboration with Instil for the PD-L1xVEGF bispecific antibody IMM2510/SYN-2510 in combination with chemotherapy for front-line non-small cell lung cancer (NSCLC) and front-line triple-negative breast cancer (TNBC).

The Company is accelerating the development of IMM2510/SYN-2510 for front-line NSCLC by targeting initiation of a Phase 1b/2 front-line chemotherapy combination study in late 2024 in China, which is expected to enroll patients with driver gene mutation-negative non-squamous and squamous NSCLC. The Company is also expediting development of IMM2510/SYN-2510 for front-line TNBC, with initial Phase 1b/2 chemotherapy combination studies targeted to begin in early 2025 in China. Instil is prioritizing

development of SYN-2510/IMM2510 for NSCLC and TNBC in the United States and targets to submit an investigational new drug (IND) application to the United States Food and Drug Administration in late 2024, starting with a Phase 2 trial of SYN-2510/IMM2510 monotherapy in second-line non-squamous and squamous NSCLC. With potential positive proof-of-concept data, the Company and Instil may initiate joint global randomized Phase 3 chemotherapy combination trials for front-line non-squamous and squamous NSCLC and/or front-line TNBC.

## **ABOUT IMM2510/SYN-2510**

IMM2510/SYN-2510 is a programmed cell death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody in development for the treatment of multiple solid tumor cancers. IMM2510/SYN-2510 is differentiated from other PD-(L)1xVEGF bispecific antibodies by its VEGF trap, which binds multiple VEGF receptor ligands beyond vascular endothelial growth factor A (VEGF-A), a bispecific structure which leverages PD-L1 as an anchor in the tumor microenvironment (TME), and enhanced antibody-dependent cellular cytotoxicity (ADCC) to direct killing of PD-L1-positive tumor cells.

## **ABOUT INSTIL**

Instil Bio, Inc. is a company incorporated in 2018 and headquartered in Dallas, Texas, the United States, which is listed on the NASDAQ Global Market (NASDAQ: TIL). It is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. For further details of Instil Bio, Inc., please refer to its website at [www.instilbio.com](http://www.instilbio.com).

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, IMM2510/SYN-2510, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board

**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

**宜明昂科生物醫藥技術(上海)股份有限公司**

**Tian Wenzhi**

*Chairman and Executive Director*

Hong Kong, September 16, 2024

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*